GSTO1-1 upregulation has been reported in various cancers, including pancreatic cancer [52], esophageal adenocarcinoma [53,54], colorectal cancer [55], and ovarian cancer, where the upregulation has been associated with drug resistance [24,56]. Here, GSTO1 is linked to ovarian carcinoma.